

Chemical Components from *Aloe* and their Inhibition of Indoleamine 2, 3-dioxygenase

Ya Nan Sun, Lin Ying Li, Wei Li¹, Jong Seong Kang, Inkyu Hwang, Young Ho Kim

College of Pharmacy, Chungnam National University, Daejeon, ¹School of Biotechnology, Yeungnam University, Gyeongsan, Gyeongbuk, Korea

Submitted: 09-03-2016

Revised: 11-07-2016

Published: 06-01-2017

ABSTRACT


Background: In Korea, *Aloe* is routinely ingested as a traditional medicine or as a component of health beverages. **Objective:** To research the inhibition of indoleamine 2, 3-dioxygenase (IDO) activities of components from *Aloe*. **Materials and Methods:** the compounds were isolated by a combination of silica gel and YMC Rp-18 column chromatography, and their structures were identified by analysis of spectroscopic data (1D, 2D-NMR, and MS). All of the isolated compounds were examined for their ability to inhibit IDO, which actively suppresses immune functions by catalyzing the rate limiting reaction in the conversion of tryptophan to kynurenine. **Results:** In this phytochemical study, 18 known compounds were isolated from aqueous dissolved *Aloe* exudates. All of the isolated compounds were examined for their ability to inhibit IDO activities for a series of anthraquinone derivatives (1-7) isolated from the *Aloe* extract; the IC₅₀ values of these compounds ranged from 39.41 to 53.93 μM. Enzyme kinetic studies of their modes of inhibition indicated that all of the compounds were uncompetitive inhibitors. **Conclusion:** The aqueous dissolved *Aloe* exudate can be used as a source of novel natural IDO inhibitors and merit testing as therapeutic agents in the treatments of cancer and immunopathologic diseases, such as autoimmune, inflammatory, and allergic disorders.

Key words: *Aloe*, anthraquinone derivatives, Asphodelaceae, indoleamine 2, 3-dioxygenase (IDO)

SUMMARY

- In this study, 18 known compounds were isolated from aqueous dissolved *Aloe* exudates. All of the isolated compounds were examined for their

ability to inhibit indoleamine 2, 3-dioxygenase (IDO) activities for a series of anthraquinone derivatives (1–7) isolated from the *Aloe* extract.



Abbreviation used: IDO: inhibit indoleamine 2, 3-dioxygenase, TMS: tetramethylsilane, HMQC: heteronuclear multiple quantum correlation, HMBC: heteronuclear multiple bond correlation, COSY: 1H-1H correlation spectroscopy, ESI-MS: Electrospray ionization mass spectrometry, DMSO: dimethyl sulfoxide

Correspondence:

Prof. Young Ho Kim,
College of Pharmacy, Chungnam National
University, Daejeon, Korea.
E-mail: yhk@cnu.ac.kr
DOI: 10.4103/0973-1296.197633

Access this article online

Website: www.phcog.com

Quick Response Code:



INTRODUCTION

Indoleamine 2, 3-dioxygenase (IDO) is an intracellular enzyme that catalyzes the transformation of L-tryptophan to *N*-formylkynurenine, which is the first and rate-controlling step in the kynurenine pathway.^[1] The role of IDO in immunomodulation has been reported in previous studies, including preclinical studies of allograft tolerance, inflammation, and cancer.^[2] Both animal and human studies have demonstrated that IDO-expressing cells function as immunosuppressors by increasing T-lymphocyte tolerance. These observations strongly suggest that IDO plays an important role in the regulation (suppression) of the adaptive immune response and thus provides an excellent therapeutic target for anticancer immunotherapy.^[3]

Aloe is a short-stemmed succulent herb what belongs to the Asphodelaceae family. The seven genera of this family include approximately 650 species.^[4] Of these, the 400 species of the genus *Aloe* typically grow in temperate and subtropical regions of Africa.^[5-7] Based on morphological characteristics,^[8] the genus *Aloe* has been divided into 20 subgroups, ranging from grass to tree aloes. In addition to its use in traditional medicines for the treatment of various diseases, aloe is an ingredient in many cosmetics and health foods. A previous phytochemical study revealed that the main constituents of *Aloe* are phenolic compounds, including anthraquinones, chromones, and pyrones.^[9-11] Aqueous *Aloe* exudates and several monomeric compounds isolated from *Aloe* exert anti-inflammatory, antioxidant, anticancer, and antidiabetic properties.^[12,13,15]

However, to our knowledge, the IDO inhibitory activity of the plant has not been reported. In the present study, 18 compounds isolated from aqueous dissolved *Aloe* exudates were evaluated for their IDO inhibitory activities. Our findings have medical and pharmacological applications.

MATERIALS AND METHODS

General experimental procedures

The NMR spectra were recorded using a JEOL ECA 600 spectrometer (¹H, 600 MHz and ¹³C, 150 MHz), with tetramethylsilane as an internal standard. Heteronuclear multiple quantum correlation, heteronuclear multiple bond correlation, and ¹H-¹H correlation spectroscopy spectra were recorded using a pulsed field gradient. The ESI-MS: Electrospray ionization mass spectrometry and DMSO: dimethyl sulfoxide, spectra

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

Cite this article as: Sun YN, Li LY, Li W, Kang JS, Hwang I, Kim YH. Chemical components from *Aloe* and their inhibition of indoleamine 2, 3-dioxygenase. *Phcog Mag* 2017;13:58-63.

were obtained by using an Agilent 1200 LC-MSD Trap spectrometer. Melting points were determined using an Electro thermal IA-9200 system. Column chromatography was performed using a silica gel (Kieselgel 60, 70-230, and 230-400 mesh, Merck, Darmstadt, Germany), YMC RP-18 resins, and thin layer chromatography was performed using pre-coated silica-gel 60 F₂₅₄ and RP-18 F_{254S} plates (both 0.25 mm, Merck, Darmstadt, Germany), the spots were detected under UV light and using 10% H₂SO₄.

Plant material

The dried exudates of *Aloe* were purchased from herbal company, Naemome Dah, Ulsan, Korea in April 2014, and identified by Prof. Young Ho Kim, College of Pharmacy, Chungnam National University. A voucher specimen (CNU14105) was deposited at the herbarium of the College of Pharmacy, Chungnam National University in Korea.

Extraction and isolation

The dried exudation of *Aloe* (200 g) were dissolved in H₂O three times under ultrasonication at ambient temperature and then filtered. The filtrate was concentrated and partitioned with CHCl₃, EtOAc, and *n*-BuOH to yield CHCl₃ (2.0 g), EtOAc (24.0 g), and *n*-BuOH (20.0 g) fractions. The EtOAc fraction (24.0 g) was subjected to silica gel (10 × 30 cm) column chromatography with a gradient of CHCl₃-MeOH-H₂O (1:0:0, 30:1:0, 15:1:0, 9:1:0, 5:1:0.1, 1:1:0.1; 2.0 L for each step) to give seven fractions (Fr. E1–E7). Fraction E2 was further chromatographed on a reverse-phase (RP; 1.0 × 80 cm) column chromatography using a gradient of MeOH-H₂O (1:4, 1:2; 500 mL each step) to give compounds 1 (37.5 mg), 10 (3.0 mg), and 11 (16.8 mg). The fraction E3 was chromatographed on an RP (1.5 × 80 cm) column with MeOH-H₂O (1:5, 1:3.5, 1:1.5, 1:1; 800 mL each step) to obtain four subfractions (E3.1–E3.4), further purification of the subfraction E3.3 by silica gel (1.0 × 60 cm) column with CHCl₃-MeOH (20:1, 15:1; 800 mL each step) led to compounds 4 (2.0 mg), 9 (3.0 mg), and 16 (15.0 mg). Subfraction E3.4 was separated using a silica gel (2.0 × 80 cm) column chromatography with a gradient of CHCl₃-MeOH (15:1, 10:1; 1 L each step) to give compounds 8 (100.0 mg) and 14 (16.0 mg). Fraction E5 was column chromatographed over RP (3.0 × 80 cm), eluting with MeOH-H₂O (1:4, 1:2, 1:1, 2:1; 1500 mL each step) to obtain five subfractions (E5.1–E5.5), then subfraction E5.3 was further chromatographed on a silica gel (1.0 × 60 cm) column chromatography with a gradient of CHCl₃-MeOH (10:1; 800 mL) to give compound 2 (50.0 mg). Subfraction E5.5 was chromatographed on a silica gel (1.0 × 80 cm) column chromatography with CHCl₃-MeOH-H₂O (6.5:1:0.1; 800 mL) to yield compound 3 (100.0 mg).

The *n*-BuOH fraction (20.0 g) was subjected to silica gel (10.0 × 30 cm) column chromatography with a gradient of CHCl₃-MeOH-H₂O (15:1:0, 10:1:0, 7:1:0.1, 4:1:0.1, 2:1:0.2; 2.0 L for each step) to give six fractions (Fr. B1–B6). The fraction B3 was subjected to RP (2.5 × 60 cm) column chromatography with a gradient of acetone-MeOH-H₂O (0.025:0.025:1, 0.1:0.1:1, 0.2:0.2:1, 0.3:0.3:1; 1.5 L for each step) to give five fractions (Fr. B3.1–B3.5). The fraction B3.2 was subjected to an silica gel (1.0 × 80 cm) column chromatography with a CHCl₃-MeOH-H₂O (7:1:0.1; 800 mL) to give compounds 13 (2.0 mg) and 15 (6.5 mg). The fraction B3.4 was separated using an RP (1.0 × 80 cm) column chromatography with an MeOH-H₂O (1:2; 800 mL) elution solvent to give compound 12 (15.0 mg). The fraction B5 was subjected to RP (2.5 × 60 cm) column chromatography with a gradient of acetone-MeOH-H₂O (0.025:0.025:1, 0.1:0.1:1, 0.2:0.2:1, 0.3:0.3:1, 0.4:0.4:1; 2.0 L for each step) to give six fractions (Fr. B5.1–B5.6). Compound 18 (20.0 mg) was isolated from fraction B5.3 using a silica gel (2.0 × 80 cm) column chromatography with CHCl₃-MeOH-H₂O (4:1:0.1; 1.0 L). Subfraction B5.5 was subjected to a silica gel (1.5 × 80 cm) column chromatography

with a CHCl₃-MeOH-H₂O (5:1:0.1; 1.0 L for each step) elution solvent to give compound 17 (20.4 mg). The fraction B6 was subjected to RP (2.5 × 60 cm) column chromatography with a gradient of acetone-MeOH-H₂O (0.025:0.025:1, 0.05:0.05:1, 0.2:0.2:1, 0.3:0.3:1, 0.4:0.4:1; 1.0 L for each step) to give seven fractions (Fr. B6.1–B6.7). Subfraction B6.5 was further purified by chromatography column over silica gel (1.0 × 80 cm) to obtain compounds 5 (15.0 mg) and 6 (3.0 mg). Compound 7 (8.0 mg) was isolated from fraction B6.7 using a silica gel (1.0 × 80 cm) column chromatography with CHCl₃-MeOH-H₂O (6.5:1:0.1; 800 mL).

IDO assay and determination of inhibition pattern of IDO inhibitors

IDO assays were performed mainly as described previously by Nakano *et al.*^[16] Briefly, a compound serially diluted in DMSO was mixed with 1 µg of purified human IDO in an IDO assay buffer (50 mM potassium phosphate buffer, pH 6.5). Then L-(+)-ascorbic acid, methylene blue, and catalase and L-tryptophan were added to the enzyme-compound mixture to final concentrations of 50 mM, 20 mM, 10 mM, 100 µg/mL, and 200 µM, respectively. The enzyme reaction mixture was incubated at 37°C for 1 hr. After incubation, the reaction mixture was supplemented with 40 µL of 30% trichloroacetic acid and heated for 15 min at 65 °C followed by centrifugation to remove the precipitate. The supernatant taken after centrifugation was mixed with an equal volume of Ehrlich's reagent (2% p-dimethylaminobenzaldehyde in acetic acid) and incubated at RT. The intensity of the color developed, which represents the concentration of L-kynurenine produced during the enzyme reaction, was measured by reading the absorbance at 480 nm wavelength.

Inhibition patterns of IDO inhibitors were determined with Lineweaver-Burk plot, for which IDO assays were run at five different L-tryptophan concentrations and four different inhibitor concentrations (0, 25, 50, 100 µM), respectively. *K_i* of IDO inhibitors were calculated from the *y*-intercept of Lineweaver-Burk plot, which is denoted by $(1 + [I]/K_i)/V_{max}$.^[17,18]

Statistical analysis

All measurements were performed independently at least triplicate. Data were expressed as the mean ± standard deviation (SD). Statistical significance is determined by one-way analysis of variance followed by Dunnett's multiple comparison test, *P* < 0.05.

RESULTS

In this study, 18 compounds (1-18) were isolated from the aqueous dissolved *Aloe* exudate. The structures of compounds 1-18 were identified based on spectroscopic data, chemical evidence, and comparisons with previously reports [Figure 1]. Their structures were elucidated as aloemodin (1),^[19] aloin A (2),^[20] aloin B (3),^[20] desoxyaloin (4),^[21] aloinoside B (5),^[22] aloinoside C (6),^[23] aloinoside D (7),^[19] aloenin aglycone (8),^[24] feroxidin (9),^[25] 7-hydroxy-5-(hydroxymethyl)-2-methylchromone (10),^[24] 5-methylresorcinol (11),^[26] aloe resin D (12),^[11] 7-*O*-methylaloesin (13),^[11] aloeresin G (14),^[27] C-2'-decoumaroylaloesin G (15),^[14] 5-((S)-2'-oxo-4'-hydroxypentyl)-2-hydroxymethylchromone (16),^[24] aloeresin A (17),^[28] and aloenin B (18).^[28]

The inhibitory activities of the 18 isolated compounds against IDO were evaluated. Menadione served as the positive control (IC₅₀: 3.71 ± 1.26 µM). The IDO inhibition of compounds 1–18 were tested at concentration of 100 µM. At this concentration, the effects of several compounds were minimal, although compounds 1–7 showed over 60% inhibition at 100 µM. The activities of these seven compounds were examined further at lower concentrations to determine their respective IC₅₀ values. Potent inhibitory activities with IC₅₀ values of 46.50 ± 1.51, 40.32 ± 0.80, 42.21 ± 1.51, 44.81 ± 1.32, 43.88 ± 1.95, 39.41 ± 1.94, and 53.93 ± 0.95 µM, were determined for compounds 1–7, respectively [Figure 2 and Table 1].




Figure 1: Structures of compounds 1–18 from *Aloe*.




Figure 2: IDO inhibitory effects of compounds 1–7, 12, and 17. * Relative to that obtained in the absence of IDO inhibitor were plotted. Concentrations (μM) of inhibitors used in the experiment are as shown.




Figure 3: The inhibition pattern of compounds 1–7. Michaelis-Menten plots with data obtained in the presence (25, 50, and 100 μM , respectively) or absence of compounds 1 (A), 2 (B), 3 (C), 4 (D), 5 (E), 6 (F), and 7 (G). Lineweaver-Burk plots [1 (H), 2 (I), 3 (J), 4 (K), 5 (L), 6 (M), 7 (N)] generated after transformation of data used in (A–G).

An analysis of the structure-activity relationships of the isolated compounds showed that compounds 1-7 all have an anthraquinone core structure. It therefore seems likely that the anthracyclone moiety is responsible at least in part for the observed inhibition of IDO.

DISCUSSION

To more precisely determine the modes of inhibition of compounds 1-7, enzyme kinetics studies employing Lineweaver-Burk (double reciprocal) plots were performed. As shown in Figure 3, regardless of the compound used, Lineweaver-Burk plots generated in the absence (0 μM) or presence of three different concentrations (25, 50, and 100 μM) of the respective compounds yielded almost parallel line. These results suggest that compounds 1-7 should be uncompetitive inhibitors [Figure 3]. Based on the notion that compounds 1-7 were uncompetitive inhibitors, their inhibition constants (K_i) were also calculated using the same plots [Table 1].

In recent years, several studies have reported IDO inhibition by various synthetic and microbial secondary products.^[29,30] However, studies on IDO inhibitors derived from plants are limited. To our knowledge, this is the first report detailing the IDO inhibitory activities of anthraquinone derivatives from *Aloe*. Our finding suggest that aqueous dissolved *Aloe* exudate can be used as a source of novel natural IDO inhibitors and merit testing as therapeutic agents in the treatments of cancer and immunopathologic diseases such as autoimmune, inflammatory, and allergic disorders. Moreover, the anthraquinone compounds identified in this study may be exploitable as templates for the synthesis of more potent and potentially clinical IDO inhibitors.

Acknowledgement

This study was supported by the Priority Research Center Program (2009-0093815) through the National Research Foundation of Korea (NRF) and Global R and D Center program (NRF-2014K1A4A3069114) and Small Grant for Exploratory Research (NRF-2015R1D1A1A02062348) from the National Research Foundation (NRF), Republic of Korea.

Table 1: The IDO inhibitory activities of compounds 1–18

Compounds	100 μM (%)	IC_{50} (μM) ^c	Type (K_i , μM)
1	67.40 \pm 2.53	46.50 \pm 1.51	Uncompetitive (85.26 \pm 2.59)
2	66.59 \pm 0.51	40.32 \pm 0.80	Uncompetitive (68.56 \pm 6.27)
3	66.78 \pm 0.82	42.21 \pm 1.51	Uncompetitive (70.21 \pm 7.46)
4	61.46 \pm 1.67	44.81 \pm 1.32	Uncompetitive (80.27 \pm 5.14)
5	74.58 \pm 1.17	43.88 \pm 1.95	Uncompetitive (77.32 \pm 0.87)
6	67.80 \pm 1.38	39.41 \pm 1.94	Uncompetitive (65.32 \pm 3.13)
7	63.03 \pm 1.84	53.93 \pm 0.95	Uncompetitive (135.45 \pm 4.68)
8	6.36 \pm 4.72	N.T. ^b	N.T. ^b
9	11.16 \pm 0.35	N.T. ^b	N.T. ^b
10	5.86 \pm 3.08	N.T. ^b	N.T. ^b
11	10.15 \pm 1.75	N.T. ^b	N.T. ^b
12	49.32 \pm 0.27	99.52 \pm 2.75	N.T. ^b
13	26.73 \pm 0.98	N.T. ^b	N.T. ^b
14	22.82 \pm 0.48	N.T. ^b	N.T. ^b
15	28.78 \pm 1.25	N.T. ^b	N.T. ^b
16	9.66 \pm 4.70	N.T. ^b	N.T. ^b
17	52.35 \pm 0.48	83.81 \pm 1.33	N.T. ^b
18	20.56 \pm 0.15	N.T. ^b	N.T. ^b
Menadione ^a	-	3.71 \pm 1.26	N.T. ^b

^aPositive control; ^bN.T. = Not tested; ^c IC_{50} values are means \pm SDs ($n = 3$).

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

- Lob S, Konigsrainer A, Rammensee HG, Opelz G, Terness P. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: Can we see the wood for the trees? *Nat Rev Cancer* 2009;9:445-52.
- Mellor AL, Munn DH. IDO expression by dendritic cells: Tolerance and tryptophan catabolism. *Nat Rev Immunol* 2004;4:762-74.
- Eleftheriadis T, Pissas G, Antoniadis G, Spanoulis A, Liakopoulos V, Stefanidis I. Indoleamine 2,3-dioxygenase increases p53 levels in alloreactive human T cells, and both indoleamine 2,3-dioxygenase and p53 suppress glucose uptake, glycolysis and proliferation. *Int Immunol* 2014;26:673-84.
- Smith GF, Vanwyk BE, Mossmer M, Viljoen A. The taxonomy of *Aloinella*, *Guillauminia* and *Lemeea* (Aloaceae). *Taxon* 1995;44:513-7.
- Mebberley DJ. The plant book; a portable dictionary of higher plants. Cambridge, UK: Cambridge University Press; 1987.
- Demissew S. The botany and chemistry of *Aloes* of Africa. *Bull Chem Soc Ethiop* 1996;10:73-88.
- Okamura N, Asai M, Hine N, Yagi A. High-performance liquid chromatographic determination of phenolic compounds in *Aloe* species. *J Chromatogr* 1996;746:225-31.
- Reynolds GW. *Aloes of tropical Africa and Madagascar*. Mbabane, Swaziland: Aloe Book Fund. 1996.
- Conner JM, Gray AI, Waterman PG, Reynolds T. Novel anthrone anthraquinone dimers from *Aloe elgonica*. *J Nat Prod* 1990;53:1362-4.
- Okamura N, Hine N, Tateyama Y, Nakazawa M, Fujioka T, Mihashi K. *et al.* Five chromones from *Aloe vera* leaves. *Phytochemistry* 1998;49:219-23.
- Duri L, Morelli CF, Crippa S, Speranza G. 6-Phenylpyrones and 5-methylchromones from *Kenya aloe*. *Fitoterapia* 2004;75:520-2.
- Hutter JA, Salman M, Stavinoha WB, Satsangi N, Williams RF, Streeper RT. *et al.* Antiinflammatory C-glucosyl chromone from *Aloe barbadensis*. *J Nat Prod* 1996;59:541-3.
- Lee KY, Weintraub ST, Yu BP. Isolation and identification of a phenolic antioxidant from *Aloe barbadensis*. *Free Radic Biol Med* 2000;28:261-5.
- Lv L, Yang QY, Zhao Y, Yao CS, Sun Y, Yang EJ. *et al.* BACE1 (beta-secretase) inhibitory chromone glycosides from *Aloe vera* and *Aloe nobilis*. *Planta Med* 2008;74:540-5.
- Abdissa N, Induli M, Fitzpatrick P, Alao JP, Sunnerhagen P, Landberg G. *et al.* Cytotoxic quinones from the roots of *Aloe dawei*. *Molecules* 2014;19:3264-73.
- Nakano S, Takai K, Isaka Y, Takahashi S, Unno Y, Ogo N. *et al.* Identification of novel kynurenine production-inhibiting benzenesulfonamide derivatives in cancer cells. *Biochem Biophys Res Commun* 2012;419:556-61.
- Kudo Y, Boyd CA. Human placental indoleamine 2,3-dioxygenase: Cellular localization and characterization of an enzyme preventing fetal rejection. *Biochim Biophys Acta* 2000;1500:119-24.
- Dolusic E, Larriue P, Moineaux L, Stroobant V, Pilotte L, Colau D. *et al.* Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(Pyridyl)ethenyl)indoles as potential anticancer immunomodulators. *J Med Chem* 2011;54:5320-34.
- Danielsen K, Aksnes DW. NMR study of some anthraquinones from Rhubarb. *Magn Reson Chem* 1992;30:359-63.
- Manitto P, Monti D, Speranza G. Studies on aloe-6-conformation and absolute configuration of aloin A and B related to 10-C-glucosyl-9-anthrone. *J Chem Soc Perk T* 1990;1:1297-300.
- Hata K, Baba K, Kozawa M. Chemical studies on the heartwood of *Cassia garrettiana* Craib. I. Anthraquinones including cassialoin, a new anthrone C-glycoside. *Chem Pharm Bull* 1987;26:3792-7.
- Gao J, Zhang GG, Dai R, Bi K. Isolation of aloin B and metabolism by rat intestinal bacteria. *Pharm Biol* 2004;42:581-7.
- Sun YN, Kim JH, Li W, Jo AR, Yan XT, Yang SY. *et al.* Soluble epoxide hydrolase inhibitory activity of anthraquinone components from *Aloe*. *Bioor Med Chem* 2015;23:6659-65.
- Zhong JS, Huang YY, Ding WJ, Wu XF, Wan JZ, Luo HB. Chemical constituents of *Aloe barbadensis* Miller and their inhibitory effects on phosphodiesterase-4D. *Fitoterapia* 2013;91:159-65.

25. Speranza G, Manitto P, Monti D, Lianza F. Feroxidin a novel 1-methyltetralin derivative isolated from cape *aloe*. *Tetrahedron Lett* 1990;31:3077-80.
26. Lee YR, Wang X. First concise synthesis of biologically interesting nigrolineabenzopyran A, (\pm)-blandachromene II, and (\pm)-daurichromene D. *B Korean Chem Soc* 2007;28:2061-4.
27. Xiao ZY, Chen DH, Si JY, Tu GZ, Ma LB. The chemical constituents of *Aloe vera* L. *Acta Pharmaceutica Sinica* 2000;35:120-3.
28. Yang QY, Yao CS, Fang WS. A new triglucosylated naphthalene glycoside from *Aloe vera* L. *Fitoterapia* 2010;81:59-62.
29. Oh WK, Lee HS, Kim BY, Ahn SC, Kang DO, Kim YH. *et al.* CRM-51005, a new phospholipase C inhibitor produced by unidentified fungal strain MT51005. *J Antibiot* 1997;50:1083-5.
30. Jang JP, Jang JH, Oh M, Son S, Kim SM, Kim HM. *et al.* Inhibition of indoleamine 2,3-dioxygenase by thielavin derivatives from a soil fungus, *Coniochaeta* sp. 10F058. *J Antibiot* 2014;67:331-3.